Age, Gender, Comorbidity, and the MDS-UPDRS: Results from a Population-Based Study
Age, Gender, Comorbidity, and the MDS-UPDRS: Results from a Population-Based Study
复制标题
DOI：
10.1159/000444021
复制
发表时间：
2016-01-01
影响因子：
5.7
通讯作者：
Postuma, Ronald B.
中科院分区：
文献类型：
--
作者：
Keezer, Mark R.;Wolfson, Christina;Postuma, Ronald B.
背景资料：了解国际帕金森和运动障碍协会统一帕金森病评定量表（MDS-MSAS）评分的变化来源对于规划帕金森病临床试验和解释轻度帕金森病体征的研究至关重要。方法：我们描述了在一个基于人群的样本没有帕金森综合征的个人的MDS-BMRS的特点。多元线性回归和斯皮尔曼等级相关系数被用来检查潜在的关联。结果：在194名无帕金森综合征的连续个体中，平均MDS-MRS总分为12.5（SD 9.8）。69%（134/193）的运动检查（第三部分）评分为2分或以上，16%（30/194）的评分为10分或以上。女性、关节炎或颈椎病、糖尿病和特发性震颤与MDS-FINS第三部分评分的统计学显著增加相关。年龄每增加10岁，第三部分评分平均增加2.2（1.5-2.8）。结论：MDS-MRS评分升高在一般人群中很常见。帕金森综合征运动体征的总体负担在老年组、女性和患有特定合并症的患者中尤其高。这是否代表亚临床神经退行性过程的证据或共病条件的影响需要进一步检查。(C)2016 S. Karger AG，巴塞尔
Background: Understanding sources of variation in International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores is essential for planning clinical trials in Parkinson's disease and interpreting studies of mild parkinsonian signs. Methods: We describe the characteristics of the MDS-UPDRS in a population-based sample of individuals without parkinsonism. Multiple linear regression and Spearman's rank correlation coefficients were used to examine potential associations. Results: Among 194 consecutive individuals without parkinsonism, the mean total MDS-UPDRS score was 12.5 (SD 9.8). Sixty-nine percent (134/193) had motor examination (Part III) scores of 2 or more, 16% (30/194) had scores of 10 or more. Female sex, arthritis or spondylosis, diabetes mellitus, and essential tremor were found to be associated with statistically significant increases in MDS-UPDRS Part III scores. For every 10-year increase in age, the Part III score was greater on average by 2.2 (1.5-2.8). Conclusions: Elevated MDS-UPDRS scores are common in the general population. The overall burden of motor signs of parkinsonism is especially high in older age groups, in women, and in those with particular comorbidities. Whether this represents evidence of a subclinical neurodegenerative process or the effect of co-morbid conditions requires further examination. (C) 2016 S. Karger AG, Basel